This study was a groundbreaking phase III trial evaluating the efficacy of combining nivolumab (anti-PD1) and ipilimumab (anti-CTLA-4) in the treatment of advanced NSCLC. Here, CTLA4 is linked to non-small cell lung carcinoma.